Crossmark Global Holdings’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.6M Buy
53,183
+646
+1% +$240K 0.27% 84
2026
Q1
$15.4M Sell
52,537
-2,857
-5% -$939K 0.23% 106
2025
Q4
$19.4M Buy
55,394
+3,392
+7% +$1.15M 0.28% 78
2025
Q3
$16.8M Sell
52,002
-1,503
-3% -$467K 0.25% 95
2025
Q2
$20.8M Buy
53,505
+31,802
+147% +$12.8M 0.34% 65
2025
Q1
$9.44M Sell
21,703
-112
-0.5% -$45K 0.17% 153
2024
Q4
$8.05M Sell
21,815
-669
-3% -$280K 0.15% 164
2024
Q3
$11.7M Sell
22,484
-16,261
-42% -$8.69M 0.21% 121
2024
Q2
$21M Sell
38,745
-9,553
-20% -$5.05M 0.4% 54
2024
Q1
$25M Sell
48,298
-1,957
-4% -$973K 0.48% 43
2023
Q4
$23.7M Buy
50,255
+427
+0.9% +$197K 0.49% 35
2023
Q3
$22.7M Sell
49,828
-23,402
-32% -$10.6M 0.51% 34
2023
Q2
$34.2M Buy
73,230
+1,630
+2% +$752K 0.74% 16
2023
Q1
$32.9M Buy
71,600
+24,219
+51% +$11.5M 0.77% 12
2022
Q4
$24.3M Buy
47,381
+1,748
+4% +$888K 0.61% 23
2022
Q3
$20.7M Buy
45,633
+787
+2% +$377K 0.58% 25
2022
Q2
$21.6M Buy
44,846
+3,572
+9% +$1.77M 0.56% 26
2022
Q1
$20.3M Buy
41,274
+9,189
+29% +$4.2M 0.45% 37
2021
Q4
$14.9M Sell
32,085
-3,304
-9% -$1.39M 0.32% 69
2021
Q3
$13.2M Buy
35,389
+10,901
+45% +$4.14M 0.31% 78
2021
Q2
$9.35M Buy
24,488
+2,081
+9% +$795K 0.22% 116
2021
Q1
$8.04M Sell
22,407
-1,483
-6% -$477K 0.2% 129
2020
Q4
$7.67M Sell
23,890
-2,874
-11% -$882K 0.19% 131
2020
Q3
$7.19M Buy
26,764
+2,629
+11% +$707K 0.2% 129
2020
Q2
$6.35M Buy
24,135
+2,503
+12% +$668K 0.19% 135
2020
Q1
$4.91M Buy
21,632
+1,041
+5% +$284K 0.18% 143
2019
Q4
$6.22M Sell
20,591
-328
-2% -$90.3K 0.17% 145
2019
Q3
$5.02M Buy
20,919
+397
+2% +$109K 0.15% 170
2019
Q2
$5.79M Buy
20,522
+1,470
+8% +$402K 0.16% 150
2019
Q1
$5.47M Sell
19,052
-2,071
-10% -$599K 0.16% 162
2018
Q4
$5.55M Sell
21,123
-907
-4% -$249K 0.17% 151
2018
Q3
$6.04M Sell
22,030
-671
-3% -$174K 0.15% 155
2018
Q2
$5.4M Sell
22,701
-666
-3% -$154K 0.15% 173
2018
Q1
$5.13M Sell
23,367
-1,592
-6% -$374K 0.13% 190
2017
Q4
$5.62M Sell
24,959
-9,147
-27% -$1.95M 0.13% 187
2017
Q3
$6.48M Buy
+34,106
New +$6.49M 0.17% 149
2016
Q3
$6.48M Buy
+34,106
New +$4.4M 0.17% 149

Other funds holding ELV

Crossmark Global Holdings's ELV Position: Q2 2026 in Review

Crossmark Global Holdings increased its Elevance Health (ELV) stake by 1.2% in Q2 2026, buying an estimated $240K and bringing the position to 53,183 shares worth $20.6M. The position accounts for 0.27% of the portfolio, ranked #84.

Crossmark Global Holdings first reported a position in ELV in Q3 2016 and has held it in 37 quarters since. The position peaked at $34.2M in Q2 2023. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Crossmark Global Holdings held 53,183 shares of Elevance Health worth $20.6M as of Q2 2026.
  • Crossmark Global Holdings bought 646 Elevance Health shares in Q2 2026, an estimated $240K.
  • Elevance Health made up 0.27% of Crossmark Global Holdings's portfolio in Q2 2026, its #84 holding.
  • Crossmark Global Holdings first reported a position in Elevance Health in Q3 2016 and has held it in 37 quarters since.
  • Crossmark Global Holdings's Elevance Health position peaked at $34.2M in Q2 2023.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.